Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4271 | WFI 5% glucose Wiki | 1.00 |
| drug115 | AMY-101 Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Phase 2/3 randomized, parallel group, 2-arm study (treatment vs. control), investigating the efficacy and safety of intravenous administration of anakinra, an interleukin 1 receptor antagonist ( IL-1), added to standard treatment, compared to standard treatment alone, to reduce hyperinflammation and respiratory distress in patients with SARS-CoV-2 infection.
Description: Treatment success, defined as number of patients not requiring mechanical ventilation by Day 15.
Measure: Treatment success, defined as number of patients not requiring mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia. Time: Day 15Description: Number of patients not requiring mechanical ventilation
Measure: Number of patients not requiring mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia. Time: Day 28Description: Time to mechanical ventilation
Measure: Time to mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia. Time: Up to 28 daysDescription: Time to oxygen saturation normalization
Measure: Time to oxygen saturation normalization to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia. Time: Up to 28 daysDescription: Stay in ICU and hospitalization
Measure: Stay in ICU and hospitalization to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia. Time: Up to 28 daysDescription: Total mortality rate
Measure: Total mortality rate to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia. Time: day 28Description: Mortality 48 hours, 7 days, in ICU and hospital
Measure: Mortality 48 hours, 7 days, in ICU and hospital to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia. Time: 48 hours, 7 daysDescription: Viral clearance / viral shedding
Measure: Viral clearance / viral shedding to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia. Time: Up to 28 daysDescription: Frequency and severity of AEs: Treatment-emergent severe fatal and life-threatening serious adverse events (SAEs), Adverse events leading to premature discontinuation of study treatment, Anaphylactic/anaphylactoid reactions, Anakinra treatment group: Severe neutropenia, Treatment-emergent laboratory abnormalities.
Measure: To assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia. Time: At day 28Description: Change (improvement) in IL-6
Measure: Change in IL-6 to assess the effect of anakinra on IL-6, ferritin, and selected biomarkers relevant for hyperinflammation, MAS and cytokine storm change from baseline. Time: During 28 daysDescription: Change (improvement) in ferritin
Measure: Change in ferritin to assess the effect of anakinra Time: During 28 daysDescription: Change (improvement) in D-dimer
Measure: Change in D-dimer to assess the effect of anakinra Time: During 28 daysDescription: Change (improvement) in TGs
Measure: Change in TGs to assess the effect of anakinra Time: During 28 daysDescription: Change (improvement) in lymphopenia
Measure: Change in lymphopenia to assess the effect of anakinra Time: During 28 daysDescription: Change (improvement) in CRP
Measure: Change in CRP to assess the effect of anakinra Time: During 28 daysDescription: Change (improvement) in ESR
Measure: Change in ESR to assess the effect of anakinra Time: During 28 daysDescription: Change (improvement) in LDH
Measure: Change in LDH to assess the effect of anakinra Time: During 28 daysDescription: Time to defervescence (fever end)
Measure: Time to defervescence to assess the effect of anakinra Time: During 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports